Nelson Prato

Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial

Carolyn T Bramante, Thomas G. Stewart, David R Boulware, Matthew W. McCarthy et autres

BACKGROUND: We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults. METHODS: The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, …

us (code pays fourni par la source)

Metformin and Time to Sustained Recovery in Adults With COVID-19

Carolyn T. Bramante, Thomas G. Stewart, David R. Boulware, Matthew W. McCarthy et autres

Importance: The effect of metformin on reducing symptom duration among outpatient adults with COVID-19 has not been studied. Objective: To assess metformin compared with placebo for symptom resolution during acute infection with SARS-CoV-2. Design, Setting, and Participants: The Accelerating COVID-19 Therapeutic Interventions …

us, gr (code pays fourni par la source)

Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia

Sean P. Collins, Matthew S. Shotwell, Jeffrey R. Strich, Kevin W. Gibbs et autres

Importance: Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19. Objective: To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia. Design, Setting, and Participants: This multicenter, phase 3, placebo-controlled, double-blinded randomized …

us, fr, es, Afrique du Sud (code pays fourni par la source)

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo

Russell L. Rothman, Thomas G. Stewart, Ahmad Mourad, David R. Boulware et autres

Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating outpatients with mild to moderate COVID-19. Design, Setting, and Participants: This randomized …

us, gr (code pays fourni par la source)

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

Thomas G. Stewart, Paulina A. Rebolledo, Ahmad Mourad, Christopher J. Lindsell et autres

Importance: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. Objective: To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19. Design, Setting, and …

us, gr (code pays fourni par la source)

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19

Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs, Marjolein de Wit et autres

Importance: Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contributor to COVID-19 pathophysiology. Objective: To evaluate the efficacy and safety …

us, fr (code pays fourni par la source)

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19

Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart et autres

Importance: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. Objective: To evaluate the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg …

us, gr (code pays fourni par la source)

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell et autres

Importance: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. Objective: To evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily) for 10 days compared with placebo for the …

us, gr (code pays fourni par la source)

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart et autres

Importance: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. Objective: To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with placebo for …

us, gr (code pays fourni par la source)

Perfil y tendencias de la producción científica en salud de Venezuela : informe final

Jorge Díaz Polanco, L. Yero, Nelson Prato